Featuring perspectives from Dr Ahmed Omar Kaseb and Prof Arndt Vogel, including the following topics:

• Introduction: EMERALD-1 — Immune Checkpoint Inhibitor-Based Therapy for Localized HCC Eligible for Embolization (0:00)
• Optimal Utilization of Immune Checkpoint Inhibitors as First-Line Therapy for Advanced HCC – Dr Kaseb (12:49)
• Incorporation of Anti-PD-1/PD-L1 Antibody-Based Approaches for Advanced Biliary Tract Cancers (BTCs) — Prof Vogel (40:24)

CME information and select publications